Physician profile
Kompal Parmar
NPI 1710270988
$12,653.21
in general payments reported to CMS, 2019-2025
44 companies · $3,649 in 2025
The $3,649 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,166 · 2020: $1,193 · 2021: $1,724 · 2022: $1,420 · 2023: $1,786 · 2024: $1,715 · 2025: $3,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,130 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,129.67 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,147.33 | 2020-2025 | |
| Lilly USA, LLC | $1,631.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,063.86 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $937.17 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $843.60 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $530.65 | 2019-2025 | |
| Novo Nordisk INC | $471.94 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Radius Health, INC. | $395.87 | 2019-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $367.09 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $339.33 | 2025 | |
| Allergan, INC. | $337.31 | 2019-2020 | |
| Astellas Pharma US INC | $312.39 | 2019-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $296.44 | 2021-2025 | Trintellix |
| Verona Pharma, INC. | $258.75 | 2025 | Ohtuvayre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.49 | 2020-2025 | Xifaxan, Trulance |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kompal Parmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.